Ricevi le ultime notizie sulle azioni ProKidney con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PROK

Ultime notizie per

ProKidney

ProKidney Corp. - Class A Ordinary Shares

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Comments

ProKidney Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO